Frontotemporal Dementia Market, By Drug Class (Cognitive Enhancers, Antidepressants, Antipsychotics, CNS Stimulants, and Other Drug Classes), By Disease Indication, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4323
|
Published Date
August 2025
|
Pages
304
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Frontotemporal Dementia Market size was valued at US$ 245.18 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.
Frontotemporal diseases are neurological disorders characterized by the degeneration of nerve cells in the brain’s frontal and temporal lobes. This group of conditions, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly impacts behavior, language, movement, and personality, impairing an individual’s ability to perform daily activities. Also known as frontotemporal lobar degeneration, these disorders involve the progressive loss of nerve cells and the gradual onset of dementia.
Frontotemporal Dementia Market- Market Dynamics
Rising Prevalence of Neurodegenerative Disorders Fuels Market Growth
The increasing prevalence of neurodegenerative disorders, particularly among aging populations and those genetically at risk, is a key driver of the frontotemporal dementia (FTD) market. FTD is one of the leading causes of early-onset dementia, with more cases being identified worldwide due to improved awareness, diagnostics, and reporting. As life expectancy rises and neurological screening becomes more accessible, the demand for effective FTD treatments continues to grow. This has prompted pharmaceutical and biotech companies to invest heavily in developing new therapies, including gene therapies and anti-tau drugs. Additionally, healthcare systems are placing greater emphasis on early detection and intervention, further fueling market expansion. Governments worldwide are also supporting this trend by funding research initiatives, enhancing healthcare infrastructure, and implementing policies aimed at improving diagnosis and treatment of neurodegenerative diseases. Given the global burden of neurodegenerative conditions, FTD remains a critical area of unmet medical need.
Frontotemporal Dementia Market- Key Insights
- According to analysis from our research analyst, the global market is projected to grow at a compound annual growth rate (CAGR) of approximately 7.20% between 2025 and 2032.
- By drug class segmentation, antidepressants are expected to hold the largest market share in 2025.
- Based on disease indication segmentation, frontotemporal dementia is anticipated to be the most common indication in 2025.
- In 2025, North America is projected to be the leading revenue-generating region.
Frontotemporal Dementia Market- Segmentation Analysis:
The Global Frontotemporal Dementia Market is segmented on the basis of Drug Class, Disease Indication, Distribution Channel, and Region.
The market is segmented into five drug classes: Cognitive Enhancers, Antidepressants, Antipsychotics, CNS Stimulants, and Other Drug Classes. Among these, antidepressants are expected to present lucrative growth opportunities during the forecast period. Antidepressant medications are widely used not only to treat depressive disorders but also to manage a range of other conditions such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain. Physicians often prescribe various types of antidepressants to improve patient outcomes. In particular, selective serotonin reuptake inhibitors (SSRIs) have demonstrated significant benefits in treating frontotemporal disorders. According to the U.S. National Institute of Mental Health (NIMH), approximately 17.3 million adults in the United States experienced at least one major depressive episode in 2023, highlighting the growing demand for effective antidepressant therapies.
Based on disease indication, the market is divided into Frontotemporal Dementia, Movement Disorders, and Primary Progressive Aphasia. The frontotemporal dementia segment holds the largest market share in 2025 and is projected to grow steadily during the forecast period from 2026 to 2030. Frontotemporal dementia encompasses a group of rare brain disorders that primarily affect the frontal and temporal lobes, leading to significant changes in personality, language, and behavior. It is often misdiagnosed as Alzheimer’s disease, although it typically manifests at a younger age, between 40 and 65 years. The Centers for Disease Control and Prevention (CDC) estimates that frontotemporal dementia affects approximately 60,000 to 70,000 individuals in the U.S., with growing awareness and improved diagnostic methods expected to drive market growth in this segment.
Frontotemporal Dementia Market- Competitive Landscape:
The frontotemporal dementia (FTD) market is rapidly evolving, with pharmaceutical giants and innovative biotech companies competing to develop effective treatments for this complex neurodegenerative disorder. Leading players such as Transposon Therapeutics, AstraZeneca plc, Alector Inc., Pfizer Inc., and Denali Therapeutics Inc. are conducting advanced research focused on disease-modifying therapies targeting tau protein accumulation and progranulin deficiencies. The market is further propelled by orphan drug designations, increasing collaborations between industry and academia, and growing investments in precision diagnostics.
Recent Developments:
- In July 2024, the FDA approved Alpha Cognition’s oral therapy, ZUNVEYL, for the treatment of Alzheimer\'s disease in the US. This novel medication features a unique dual mechanism of action that enhances cognitive function while offering better tolerability compared to existing treatments. ZUNVEYL represents a promising advancement in Alzheimer\'s care, addressing unmet needs for patients and caregivers.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FRONTOTEMPORAL DEMENTIA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Transposon Therapeutics
- AstraZeneca plc
- Alector Inc.
- Pfizer Inc.
- Denali Therapeutics Inc.
- Johnson & Johnson Services Inc.
- Prevail Therapeutics
- Wave Life Sciences
- GlaxoSmithKline plc
- TauRx Pharmaceuticals Ltd.
- Others
GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Cognitive Enhancers
- Antidepressants
- Antipsychotics
- CNS Stimulants
- Other Drug Classes
GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032
- Frontotemporal Dementia
- Movement Disorders
- Primary Progressive Aphasia
GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
GLOBAL FRONTOTEMPORAL DEMENTIA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Frontotemporal Dementia Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Frontotemporal Dementia Market Snippet by Drug Class
2.1.2. Frontotemporal Dementia Market Snippet by Disease Indication
2.1.3. Frontotemporal Dementia Market Snippet by Distribution Channel
2.1.4. Frontotemporal Dementia Market Snippet by Country
2.1.5. Frontotemporal Dementia Market Snippet by Region
2.2. Competitive Insights
3. Frontotemporal Dementia Key Market Trends
3.1. Frontotemporal Dementia Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Frontotemporal Dementia Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Frontotemporal Dementia Market Opportunities
3.4. Frontotemporal Dementia Market Future Trends
4. Frontotemporal Dementia Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Frontotemporal Dementia Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Frontotemporal Dementia Market Landscape
6.1. Frontotemporal Dementia Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Frontotemporal Dementia Market – By Drug Class
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
7.1.2. Cognitive Enhancers
7.1.3. Antidepressants
7.1.4. Antipsychotics
7.1.5. CNS Stimulants
7.1.6. Other Drug Classes
8. Frontotemporal Dementia Market – By Disease Indication
8.1. Overview
8.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
8.1.2. Frontotemporal Dementia
8.1.3. Movement Disorders
8.1.4. Primary Progressive Aphasia
9. Frontotemporal Dementia Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
9.1.2. Hospital Pharmacies
9.1.3. Online Pharmacies
9.1.4. Retail Pharmacies
10. Frontotemporal Dementia Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Frontotemporal Dementia Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Frontotemporal Dementia Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Frontotemporal Dementia Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Frontotemporal Dementia Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Frontotemporal Dementia Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Frontotemporal Dementia Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Transposon Therapeutics
11.2.2. AstraZeneca plc
11.2.3. Alector Inc.
11.2.4. Pfizer Inc.
11.2.5. Denali Therapeutics Inc.
11.2.6. Johnson & Johnson Services Inc.
11.2.7. Prevail Therapeutics
11.2.8. Wave Life Sciences
11.2.9. GlaxoSmithKline plc
11.2.10. TauRx Pharmaceuticals Ltd.
11.2.11. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
